First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma

No abstract is available for this paper.

• Publication year

  2007

• Venue

  European Journal of Haematology

• Publication date

  2007-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1600-0609.2007.00902.xPMID 17655704
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma.

  2006cited by this paper
• Red Autofluorescence of Dental Plaque Bacteria

  2006cited by this paper
• Synergistic antimyeloma effects of zoledronate and simvastatin

  2006cited by this paper
• The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.

  2004cited by this paper
• Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

  2003cited by this paper
• Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.

  2003cited by this paper
• The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

  2002cited by this paper
• Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

  1999cited by this paper
• New insights into the pharmacodynamic and pharmacokinetic properties of statins.

  1999cited by this paper
• Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

  1996cited by this paper
• Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein.

  1994cited by this paper

• Molecular basis for targeting Caveolin-1 in multiple myeloma therapy

  2026cites this paper
• Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction

  2024cites this paper
• The lipid droplet in cancer: From being a tumor‐supporting hallmark to clinical therapy

  2024cites this paper
• Targeting Caveolin‐1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell‐Mediated Immunotherapy

  2024cites this paper
• Repurposing simvastatin in cancer treatment: an updated review on pharmacological and nanotechnological aspects

  2024cites this paper
• Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment

  2023cites this paper
• Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors

  2023cites this paper
• Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance

  2023cites this paper
• Drug repositioning: Progress and challenges in drug discovery for various diseases

  2022cites this paper
• Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma

  2022cites this paper
• Simvastatin Inhibits Tumor Growth and Migration by Mediating Caspase-1-dependent Pyroptosis in Glioblastoma Multiforme.

  2022cites this paper
• Suppression of multiple myeloma by mitochondrial targeting

  2021cites this paper
• The Mevalonate Pathway, a Metabolic Target in Cancer Therapy

  2021cites this paper
• Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma.

  2021cites this paper
• Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer

  2021cites this paper
• Oxidatively modified low‐density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma

  2021cites this paper
• Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance

  2021cites this paper
• The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma

  2020cites this paper
• A remarkable in vitro cytotoxic, cell cycle arresting and proapoptotic characteristics of low-dose mixed micellar simvastatin combined with alendronate sodium

  2020cites this paper
• Recycling the Purpose of Old Drugs to Treat Ovarian Cancer

  2020cites this paper
• Statin use is associated with improved survival in multiple myeloma: A Swedish population‐based study of 4315 patients

  2020cites this paper
• Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma

  2019cites this paper
• Omega-3 fatty acids, membrane remodeling and cancer prevention.

  2018cites this paper
• Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells

  2018cites this paper
• The poor design of clinical trials of statins in oncology may explain their failure - Lessons for drug repurposing.

  2018cites this paper
• Characterization of carfilzomib-resistant non-small cell lung cancer cell lines

  2018cites this paper
• Gamma-tocotrienol reverses multidrug resistance of breast cancer cells with a mechanism distinct from that of atorvastatin.

  2017cites this paper
• Statins Are Associated With Reduced Mortality in Multiple Myeloma.

  2016cites this paper
• Clinical use of statins in hematopoietic stem cell transplantation: Old drugs and new horizons

  2016cites this paper
• Downregulation of connective tissue growth factor reduces migration and invasiveness of osteosarcoma cells.

  2016cites this paper
• Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study.

  2016cites this paper
• Novel Effects of Simvastatin on Uterine Fibroids: In vitro and Patient-Derived Xenograft Mouse Model Study

  2015cites this paper
• Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?

  2015cites this paper
• Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study.

  2015cites this paper
• Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells

  2015cites this paper
• Statins are potential anticancerous agents (review).

  2015cites this paper
• Simvastatin Potently Induces Calcium-dependent Apoptosis of Human Leiomyoma Cells*

  2014cites this paper
• Rho-GTPases and Statins: A Potential Target and a Potential Therapeutic Tool Against Tumors?

  2014cites this paper
• Akt signaling and coordinated changes in the distribution and expression of akt-regulating phosphatases

  2014cites this paper
• Preclinical Potentiators of Statin-induced Anticancer Effects

  2014cites this paper
• Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition.

  2013cites this paper
• HIGH DOSE SIMVASTATIN AS A POTENTIAL ANTICANCER THERAPY IN LEUKEMIA PATIENTS

  2013cites this paper
• Candidate cancer-targeting agents identified by expression-profiling arrays

  2013cites this paper
• Targeting the NF-κB pathway in cancer therapy.

  2013cites this paper
• The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review.

  2012cites this paper
• Targeting tumor cell metabolism with statins

  2012cites this paper
• The Hedgehog Receptor Patched Functions in Multidrug Transport and Chemotherapy Resistance

  2012cites this paper
• Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma

  2012cites this paper
• The evolving role of statins in hematopoietic stem and progenitor cell transplantation.

  2011cites this paper
• Common cardiovascular medications in cancer therapeutics.

  2011cites this paper
• Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells.

  2011cites this paper
• A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells.

  2011cites this paper
• CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis

  2011cites this paper
• Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity

  2011cites this paper
• Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.

  2011cites this paper
• Molecular Rationale and Determinants of Sensitivity for Statin-Induced Apoptosis of Human Tumour Cells

  2011cites this paper
• Modulating mesenchymal stromal cell function with cholesterol synthesis inhibitors.

  2011cites this paper
• Overcoming multidrug-resistance in cancer: statins offer a logical candidate.

  2010cites this paper
• PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells

  2010cites this paper
• Targeting the mevalonate pathway in multiple myeloma.

  2010cites this paper
• Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma.

  2010cites this paper
• Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance

  2010cites this paper
• Therapeutic modulation of k-ras signaling in colorectal cancer.

  2010cites this paper
• The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.

  2009cites this paper
• Environment-mediated drug resistance: a major contributor to minimal residual disease

  2009cites this paper
• The use of statins in hematopoietic stem cell transplantation.

  2009cites this paper
• Statins in tumor suppression.

  2008influential citation
• Progress in drug therapy for multiple myeloma

  2008cites this paper
• Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

  2008cites this paper
• Targeting p53 to mitochondria for cancer therapy

  2008cites this paper
• The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma.

  2008cites this paper
• ANTI-ADHESION evolves to a promising therapeutic concept in oncology.

  2008cites this paper
• Statins-mediated inhibition of rho GTPases as a potential tool in anti-tumor therapy.

  2008cites this paper
• HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.

  2008cites this paper
• Statins in prevention and therapy of cancer

  2008cites this paper